Login to Your Account



Fibroids Therapy in the Pipeline, Too

Repros Lifts Weighty Offering: $71M for Hypogonadism Work

By Randy Osborne
Staff Writer

Friday, June 21, 2013

Plowing ahead with the second Phase III trial to evaluate Androxal (enclomiphene), the estrogen receptor antagonist for secondary hypogonadism, Repros Therapeutics Inc. priced an underwritten public offering of about 3.7 million shares at $19 each, grossing about $71.2 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription